SCHEMBL4906817

SCHEMBL4906817

NC(=O)Nc1c(CC2CCC(CN3CCN(c4cccc(Cl)c4Cl)CC3)CC2)nn2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 16/20 0.51
DRD3 P35462 11/20 0.48
DRD4 P21917 4/20 0.43
HTR2A P28223 3/20 0.42
HTR1A P08908 2/20 0.42
ADRA2A P08913 2/20 0.42
HTR2C P28335 2/20 0.42
HTR7 P34969 2/20 0.42
ADRA1A P35348 2/20 0.42
HRH1 P35367 2/20 0.42
ABCB11 O95342 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42
HTR2B P41595 1/20 0.42
KCNH2 Q12809 1/20 0.42
SLC6A4 P31645 2/20 0.42
CHRM4 P08173 1/20 0.42
ADRB1 P08588 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915552 0.88 DRD2 (0.50) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4906834 0.85 DRD2 (0.46) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4906823 0.74 DRD2 (0.49) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4906820 0.74 DRD2 (0.49) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4915554 0.73 DRD2 (0.50) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4915556 0.73 DRD2 (0.50) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4907729 0.73 DRD2 (0.47) DRD2DRD3DRD4HTR2AHTR1A
SCHEMBL4913794 0.69 DRD2 (0.62) DRD2DRD3DRD4SLC6A4SLC6A2
SCHEMBL4913790 0.69 DRD2 (0.62) DRD2DRD3DRD4SLC6A4SLC6A2
SCHEMBL22302951 0.68 DRD2 (0.81) DRD2DRD3DRD4HTR2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP claimed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US claimed
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP disclosed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US disclosed
EP-1778685-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2007-05-02 EP disclosed
WO-2006015737-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof GRIN2A, GRIN2C, GRIN1 DRD2 248/4885DRD3 474/4885DRD4 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.